F8632
Fmoc-Ala-OH
Synonym(s):
N-(9-Fluorenylmethoxycarbonyl)-L-alanine, Fmoc-L-alanine
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C18H17NO4
CAS Number:
Molecular Weight:
311.33
EC Number:
252-660-6
UNSPSC Code:
12352200
MDL number:
Beilstein/REAXYS Number:
2225975
mp
147-153 °C (lit.)
storage temp.
−20°C
SMILES string
C[C@H](NC(=O)OCC1c2ccccc2-c3ccccc13)C(O)=O
InChI
1S/C18H17NO4/c1-11(17(20)21)19-18(22)23-10-16-14-8-4-2-6-12(14)13-7-3-5-9-15(13)16/h2-9,11,16H,10H2,1H3,(H,19,22)(H,20,21)/t11-/m0/s1
InChI key
QWXZOFZKSQXPDC-NSHDSACASA-N
Still not finding the right product?
Explore all of our products under Fmoc-Ala-OH
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
K R Sunil Kumar et al.
ACS nano, 8(5), 4157-4165 (2014-04-01)
To apply motor proteins as natural nanomolecular machines to transporting systems in nanotechnology, complete temporal control over ON/OFF switching of the motility is necessary. We have studied the photoresponsive inhibition properties of azobenzene-tethered peptides for regulation of kinesin-microtubule motility. Although
Ngoc-Duc Doan et al.
Journal of peptide science : an official publication of the European Peptide Society, 21(5), 387-391 (2014-11-18)
The solid-phase synthesis of azapeptides possessing a C-terminal aza-residue has been accomplished by a protocol featuring regioselective alkylation of benzhydrylidene-aza-glycinamide and illustrated by the syntheses of [aza-Lys(6)] growth-hormone-releasing peptide-6 analogs.
Soo Min Cho et al.
Scientific reports, 4, 6777-6777 (2014-10-28)
Amyloid-β (Aβ) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing Aβ levels in the cerebrospinal fluid (CSF) during the development of Alzheimer's disease (AD), the link